

Selenoprotein P: Diagnostischer Marker der Selenversorgung

Dr. rer. nat. Dorte Aasland
Erich-Dombrowski-Straße 3
55127 Mainz | Deutschland
dr.aasland@ganzimmun.de

Literatur

- [1] Schomburg L et al. (2004) Selenium and selenoproteins in mammals: extraordinary, essential, enigmatic. *Cell Mol Life Sci*, 61(16):1988–1995.
- [2] Schomburg L (2022) Selenoprotein P - Selenium transport protein, enzyme and biomarker of selenium status. *Free Radic Biol Med*, 191:150–163.
- [3] Hariharan S, Dharmaraj S (2020) Selenium and selenoproteins: its role in regulation of inflammation. *Inflammopharmacol*, 28(3):667–695.
- [4] Hill KE et al. (2012) Production of Selenoprotein P (Sepp1) by hepatocytes is central to selenium homeostasis. *J Biol Chem*, 287(48):40414–40424.
- [5] Saito Y (2021) Selenium Transport Mechanism via Selenoprotein P-Its Physiological Role and Related Diseases. *Front Nutr*, 8:685517.
- [6] Tsutsumi R, Saito Y (2020) Selenoprotein P; P for Plasma, Prognosis, Prophylaxis, and More. *Biol Pharm Bull*, 43(3):366–374.
- [7] Saito Y (2020) Selenoprotein P as an in vivo redox regulator: disorders related to its deficiency and excess. *J Clin Biochem Nutr*, 66(1):1–7.
- [8] Labunskyy VM et al. (2014) Selenoproteins: molecular pathways and physiological roles. *Physiol Rev*, 94(3):739–777.
- [9] Burk RF, Hill KE (2009) Selenoprotein P-expression, functions, and roles in mammals. *Biochim Biophys Acta*, 1790(11):1441–1447.
- [10] Jin Y et al. (2020) Apolipoprotein E-mediated regulation of Selenoprotein P transportation via exosomes. *Cell Mol Life Sci*, 77(12):2367–2386.
- [11] Kurokawa S et al. (2014) Isoform-specific binding of Selenoprotein P to the -propeller domain of apolipoprotein E receptor 2 mediates selenium supply. *J Biol Chem*, 289(13):9195–9207.
- [12] Genchi G et al. (2023) Biological Activity of Selenium and Its Impact on Human Health. *Int J Mol Sci*, 24(3):2633.
- [13] Köhrle J (2023) Selenium, Iodine and Iron-Essential Trace Elements for Thyroid Hormone Synthesis and Metabolism. *Int J Mol Sci*, 24(4):3393.
- [14] Wang F et al. (2023) Selenium and thyroid diseases. *Front Endocrinol (Lausanne)*, 14:1133000.
- [15] Hybsier S et al. (2017) Sex-specific and inter-individual differences in biomarkers of selenium status identified by a calibrated ELISA for Selenoprotein P. *Redox Biol*, 11:403–414.
- [16] Schöttker B et al. (2024) Strong associations of serum Selenoprotein P with all-cause mortality and mortality due to cancer, cardiovascular, respiratory and gastrointestinal diseases in older German adults. *Eur J Epidemiol*, 39(2):121–136.
- [17] Solovyev N et al. (2021) Selenium at the Neural Barriers: A Review. *Front Neurosci*, 15:630016.
- [18] Combs GF et al. (2011) Determinants of selenium status in healthy adults. *Nutr J*, 10:75.
- [19] Casanova P, Monleon D (2023) Role of selenium in type 2 diabetes, insulin resistance and insulin secretion. *World J Diabetes*, 14(3):147–158.
- [20] Kipp AP et al. (2015) Revised reference values for selenium intake. *J Trace Elem Med Biol*, 32:195–199.
- [21] Hoefflich J et al. (2010) The choice of biomarkers determines the selenium status in young German vegans and vegetarians. *Br J Nutr*, 104(11):1601–1604.
- [22] Combs GF (2015) Biomarkers of selenium status. *Nutrients*, 7(4):2209–2236.
- [23] Bundesinstitut für Risikobewertung (2024) Aktualisierung (2023): Höchstmengenvorschläge für Selen in Lebensmitteln inklusive Nahrungsergänzungsmitteln: Stellungnahme Nr. 010/2024 des BfR vom 22. Februar 2024.
- [24] Deutsche Gesellschaft für Ernährung e.V. DACH Referenzwerte, <https://www.dge.de/wissenschaft/referenzwerte/gesamt/>, Zuletzt geprüft am 06.03.2023.
- [25] Brodin O et al. (2020) Selenoprotein P as Biomarker of Selenium Status in Clinical Trials with Therapeutic Dosages of Selenite. *Nutrients*, 12(4):1067.
- [26] Filipowicz D et al. (2021) The rationale for selenium supplementation in patients with autoimmune thyroiditis, according to the current state of knowledge. *Endokrynol Pol*, 72(2):153–162.
- [27] Hackler J et al. (2023) High throughput drug screening identifies resveratrol as suppressor of hepatic SELENOP expression. *Redox Biol*, 59:102592.
- [28] Isobe Y et al. (2021) Alcohol Intake Is Associated With Elevated Serum Levels of Selenium and Selenoprotein P in Humans. *Front Nutr*, 8:633703.
- [29] Isobe Y et al. (2021) Corrigendum: Alcohol Intake Is Associated With Elevated Serum Levels of Selenium and Selenoprotein P in Humans. *Front Nutr*, 8:696947.
- [30] Rock C, Moos PJ (2009) Selenoprotein P regulation by the glucocorticoid receptor. *Biomaterials*, 22(6):995–1009.

- [31] Schwarz M et al. (2023) Excessive copper impairs intrahepatocyte trafficking and secretion of Selenoprotein P. *Nat Commun*, 14(1):3479.
- [32] Schomburg L (2021) Selenium Deficiency Due to Diet, Pregnancy, Severe Illness, or COVID-19-A Preventable Trigger for Autoimmune Disease. *Int J Mol Sci*, 22(16):8532.
- [33] Misu H (2018) Pathophysiological significance of hepatokine overproduction in type 2 diabetes. *Diabetol Int*, 9(4):224–233.
- [34] Misu H (2019) Identification of hepatokines involved in pathology of type 2 diabetes and obesity. *Endocr J*, 66(8):659–662.
- [35] Oo SM et al. (2018) Serum Selenoprotein P, but not selenium, predicts future hyperglycemia in a general Japanese population. *Sci Rep*, 8(1):16727.
- [36] Steinbrenner H et al. (2022) The role of selenium in type-2 diabetes mellitus and its metabolic comorbidities. *Redox Biol*, 50:102236.
- [37] Demircan K et al. (2023) Sex-specific associations of serum selenium and Selenoprotein P with type 2 diabetes mellitus and hypertension in the Berlin Aging Study II. *Redox Biol*, 65:102823.
- [38] Choi HY et al. (2013) Increased Selenoprotein P levels in subjects with visceral obesity and nonalcoholic fatty liver disease. *Diabetes Metab J*, 37(1):63–71.
- [39] Ke Y et al. (2019) Role of Hepatokines in Non-alcoholic Fatty Liver Disease. *J Transl Int Med*, 7(4):143–148.
- [40] Yu R et al. (2022) Associations between Circulating SELENOP Level and Disorders of Glucose and Lipid Metabolism: A Meta-Analysis. *Antioxidants (Basel)*, 11(7):1263.
- [41] Al-Mubarak AA et al. (2022) High selenium levels associate with reduced risk of mortality and new-onset heart failure: data from PREVENT. *Eur J Heart Fail*, 24(2):299–307.
- [42] Al-Mubarak AA et al. (2021) Selenium, Selenoproteins, and Heart Failure: Current Knowledge and Future Perspective. *Curr Heart Fail Rep*, 18(3):122–131.
- [43] Jujic A et al. (2019) Selenoprotein P Deficiency and Risk of Mortality and Rehospitalization in Acute Heart Failure. *J Am Coll Cardiol*, 74(7):1009–1011.
- [44] Jujic A et al. (2023) Selenoprotein P deficiency is associated with higher risk of incident heart failure. *Free Radic Biol Med*, 207:11–16.
- [45] Schomburg L et al. (2019) Selenoprotein-P Deficiency Predicts Cardiovascular Disease and Death. *Nutrients*, 11(8):1852.
- [46] Brezina S et al. (2025) Colorectal cancer mortality is associated with low Selenoprotein P status at diagnosis. *Redox Biol*, 84:103701.
- [47] Demircan K et al. (2021) Serum selenium, Selenoprotein P and glutathione peroxidase 3 as predictors of mortality and recurrence following breast cancer diagnosis: A multicentre cohort study. *Redox Biol*, 47:102145.
- [48] Mukhtar M et al. (2022) The Associations of Selenoprotein Genetic Variants with the Risks of Colorectal Adenoma and Colorectal Cancer: Case-Control Studies in Irish and Czech Populations. *Nutrients*, 14(13):2718.
- [49] Vinceti M et al. (2023) Selenoprotein P concentrations and risk of progression from mild cognitive impairment to dementia. *Sci Rep*, 13(1):8792.
- [50] Urbano T et al. (2022) Selenoprotein P Concentrations in the Cerebrospinal Fluid and Serum of Individuals Affected by Amyotrophic Lateral Sclerosis, Mild Cognitive Impairment and Alzheimer's Dementia. *Int J Mol Sci*, 23(17):9865.
- [51] Jujic A et al. (2024) Low Levels of Selenoprotein P Are Associated With Cognitive Impairment in Patients Hospitalized for Heart Failure. *J Card Fail*, 30(11):1452–1461.
- [52] Federige MA et al. (2017) Serum selenium and selenoprotein-P levels in autoimmune thyroid diseases patients in a select center: a transversal study. *Arch. Endocrinol. Metab.*, 61(6):600–607.
- [53] Baran A et al. (2020) Higher Serum Selenoprotein P Level as a Novel Inductor of Metabolic Complications in Psoriasis. *Int J Mol Sci*, 21(13):4594.